- Home
- SISI vs SYBX Comparison
SISI vs SYBX Comparison
Compare SISI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- SYBX
- Stock Information
- Founded
- SISI 1997
- SYBX N/A
- Country
- SISI China
- SYBX United States
- Employees
- SISI N/A
- SYBX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- SYBX Health Care
- Exchange
- SISI Nasdaq
- SYBX Nasdaq
- Market Cap
- SISI 17.9M
- SYBX 16.5M
- IPO Year
- SISI 2016
- SYBX N/A
- Fundamental
- Price
- SISI $0.89
- SYBX $1.20
- Analyst Decision
- SISI
- SYBX
- Analyst Count
- SISI 0
- SYBX 0
- Target Price
- SISI N/A
- SYBX N/A
- AVG Volume (30 Days)
- SISI 128.8K
- SYBX 6.3K
- Earning Date
- SISI 05-14-2025
- SYBX 03-06-2025
- Dividend Yield
- SISI N/A
- SYBX N/A
- EPS Growth
- SISI N/A
- SYBX N/A
- EPS
- SISI N/A
- SYBX N/A
- Revenue
- SISI $11,072,553.00
- SYBX $8,000.00
- Revenue This Year
- SISI N/A
- SYBX N/A
- Revenue Next Year
- SISI N/A
- SYBX N/A
- P/E Ratio
- SISI N/A
- SYBX N/A
- Revenue Growth
- SISI 145.88
- SYBX N/A
- 52 Week Low
- SISI $0.73
- SYBX $1.15
- 52 Week High
- SISI $117.65
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- SISI 44.31
- SYBX 34.47
- Support Level
- SISI $0.85
- SYBX $1.27
- Resistance Level
- SISI $1.27
- SYBX $1.32
- Average True Range (ATR)
- SISI 0.16
- SYBX 0.05
- MACD
- SISI 0.02
- SYBX -0.01
- Stochastic Oscillator
- SISI 30.64
- SYBX 17.81
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.